- 8.26.2026
- News
MDMA and the FDA, Take Two
VETS Policy Director Logan Davidson weighs in on Resilient Pharmaceuticals' renewed FDA application for MDMA-assisted therapy, calling it a meaningful step toward the rigorous, science-backed treatment options veterans with treatment-resistant PTSD deserve.
- 8.20.2026
- News
VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans
President Trump announced that HHS Secretary RFK Jr. received the University of Miami's original 1994 ibogaine FDA application to accelerate psychedelic research access for veterans, with VETS co-founder and CEO Amber Capone comments that "veterans need to understand that these treatments are not for everyone and they need careful screening, medical oversight, preparation, and follow-up."
- 7.13.2026
- News
Massachusetts House Advances Psychedelic Therapy Pilot Program
Massachusetts lawmakers advanced legislation to create a five-year psychedelic-assisted therapy pilot program, with VETS playing a key advocacy role by supporting the measure and celebrating it as a major step toward expanding safe, regulated access to psychedelic-assisted therapy for veterans and others with serious mental health conditions.
- 7.8.2026
- News
Utahns are traveling abroad for ibogaine, while experts voice both optimism and caution around the emerging drug.
The article spotlights VETS Foundational Healing Grant recipient Kyle Bingham, a former Green Beret who shares how ibogaine treatment and ongoing integration support helped him better manage PTSD while underscoring the promise and complexities of psychedelic-assisted therapy.
- 7.2.2026
- News
Why Are Republicans Suddenly for Ibogaine?
The article highlights VETS’ leadership in expanding access to psychedelic-assisted therapy, showcasing how the organization funds veterans’ ibogaine treatment abroad, provides critical integration support, and advances state and federal policy efforts to accelerate research and establish safe, regulated clinical access in the United States.